Skip to Content
Merck
  • Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma.

Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma.

Oncotarget (2012-08-30)
Valentina Bevelacqua, Ylenia Bevelacqua, Saverio Candido, Evangelia Skarmoutsou, Alfredo Amoroso, Claudio Guarneri, Angela Strazzanti, Pietro Gangemi, Maria C Mazzarino, Fabio D'Amico, James A McCubrey, Massimo Libra, Grazia Malaponte
ABSTRACT

NECL-5 is involved in regulating cell-cell junctions, in cooperation with cadherins, integrins and platelet-derived growth factor receptor, that are essential for intercellular communication. Its role in malignant transformation was previously described. It has been reported that transformation of melanocytes is associated with altered expression of adhesion molecules suggesting the potential involment of NECL-5 in melanoma development and prognosis. To shed light on this issue, the expression and the role of NECL-5 in melanoma tissues was investigated by bioinformatic and molecular approaches. NECL-5 was up-regulated both at the mRNA and the protein levels in WM35, M14 and A375 cell lines compared with normal melanocytes. A subsequent analysis in primary and metastatic melanoma specimens confirmed "in vitro" findings. NECL-5 overexpression was observed in 53 of 59 (89.8%) and 12 of 12 (100%), primary melanoma and melanoma metastasis, respectively; while, low expression of NECL-5 was detected in 12 of 20 (60%) benign nevi. A significant correlation of NECL-5 overexpression was observed with most of known negative melanoma prognostic factors, including lymph-node involvement (P = 0.009) and thickness (P = 0.004). Intriguingly, by analyzing the large series of melanoma samples in the Xu dataset, we identified the transcription factor YY1 among genes positively correlated with NECL-5 (r = 0.5). The concordant computational and experimental data of the present study indicate that the extent of NECL-5 expression correlates with melanoma progression.